Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Cambridge: Biogen
In the Lab

7 burning questions now that Biogen has resurrected its ‘failed’ Alzheimer’s drug

By Sharon Begley

Steven St. Peter
Biotech

The country’s only diabetes-focused venture fund brings on a new partner

By Kate Sheridan

Cambridge: Biogen
Biotech

Experts parse Biogen’s Alzheimer’s data: Does the treatment work, or is it a mirage?

By Sharon Begley and Damian Garde

Business

Novartis gene therapy brings in $160 million, beating expectations

By Rebecca Robbins and Damian Garde

Biotech

In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval

By Matthew Herper

John Butler - Akebia Therapeutics
Biotech

This small biotech is suing the Trump administration to get its drug covered

By Nicholas Florko

Business

This is awkward: Genome editing startup Beam has competition — from one of its own cofounders

By Adam Feuerstein and Damian Garde

Breast Cancer Cell - pink
Biotech

Seattle Genetics to seek approval for new breast cancer pill after positive clinical trial results

By Adam Feuerstein

wework
Biotech

A biotech real estate firm wants a new slogan. WeWork says not so fast

By Kate Sheridan

biotech invest
Biotech

Biotech worries new trade rules could sap foreign investment

By Damian Garde

Unnatural Selection Season 1 Episode 1 - Option 2
Biotech

The ‘unbelievable journey’ of CRISPR, now on Netflix

By Damian Garde and Adam Feuerstein

Epidiolex
Biotech

The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism

By Nicholas Florko

Sean Parker
Biotech

Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground

By Adam Feuerstein

Cannabis cultivation
Biotech

These four companies are betting big on CBD-based prescription drugs

By Nicholas Florko

DNA Strand - Abstract
Biotech

Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder

By Jonathan Saltzman — Boston Globe

Alexion Pharmaceuticals Inc
Biotech

Alexion acquiring Achillion to expand reach into rare, immune-related disease

By Adam Feuerstein

Amazon health/stock market
Biotech

‘Gene therapy headwinds’ are blamed for biotech stock woes

By Adam Feuerstein

Test tubes and pipette
Biotech

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

By Jonathan Saltzman — Boston Globe

Play
Biotech

Watch: How biotech startups become unicorns, explained

By Damian Garde

Lots of people
Biotech

How Colorado firefighters, a Hawaiian charity, and TV writers are fueling the biotech boom

By Kate Sheridan

Biotech

Archived chat: An online discussion about the Q4 biotech scorecard

By Adam Feuerstein

Courtesy Julia Vitarello
Biotech

After a bespoke therapy rescues a young girl, the FDA considers advance of individualized treatments

By Meghana Keshavan

Pharmalot

A small biotech raises the price on its cancer drug by 20% this year, but will anyone notice?

By Ed Silverman

Adam's Take

A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling

By Adam Feuerstein

Nobel Prize Medal
Biotech

These 4 biotechs are already bragging about their ‘Nobel Prize-winning’ bona fides

By Kate Sheridan

Sarepta - Cambridge -AP
Biotech

Sarepta gene therapy improves muscle function for patients with rare limb-girdle disease

By Adam Feuerstein

Dr Ben Davies
Biotech

‘It’s really a horrific situation’: What one doctor thinks about drug shortages‚ and how to solve them

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

RNA illustration
Health

Beyond DNA testing: Can analyzing RNA turn up more patients at risk of cancer?

By Rebecca Robbins

Biotech

Sarepta under new pressure as a competitor files with FDA for Duchenne drug

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy